Hi! Welcome back!

Monitor GI research programs, inspect questionnaire intelligence, and launch new evidence workflows from one clinical command center.

3 active programs580 verified doctors314 responses

All Programs

Track program progress, sends, completions, patient links, and status.

3 active

Dashboard

Analyze every questionnaire item with insights, patterns, and actions.

180 responses

Lab Data

Explore national GI lab signals, abnormality rates, biomarker uptake, and care gaps.

12.85M tests

Demo Screens

Preview the patient mobile journey, doctor workspace, and response flow.

Patient View

Gastro QualLife

Open a GI quality-of-life questionnaire for physicians or direct patient links.

Questionnaire

HCP Vignette Survey

Run specialist clinical vignettes across NAFLD, GERD, and IBS decisions.

36 questions

Create a New Program

Set up a new KAP, PRO, or registry workflow with audience and instruments.

Start

National diagnostic network · Real-world evidence · Gastroenterology vertical

The GI lab landscape, at a glance

A clinician-facing view of GI diagnostic ordering and result patterns: test volume, abnormality rates among tested patients, guideline-concordant workup signals, and potential gaps requiring validation.

Last updated 26 May 2026 184 labs · pan-India

Region

Window

Age

Active lab cohort

All India · Last 12 mo · All ages

Tests / window12.85M

+18.2% YoY · across GI-relevant assays

Unique patients3.41M

Approx. 3.8 tests per patient encounter

Abnormal share31.4%

Any GI panel flagged out of range

Top categoryLFT

27.8% of GI lab test mix

Guideline adherence54.7%

Recommended workup completeness

Molecular uptake1.8%

MSI · RAS · HER2 · BRCA and related tests

Test mix · share of GI-relevant orders

What gastroenterology orders look like, in volume

Liver and viral hepatitis testing together account for nearly 40% of GI lab demand.

Volume trend · monthly orders

Demand has been climbing, with calprotectin and molecular fastest

Indexed monthly volume across high-traffic GI categories.

Abnormality signal

What is coming back abnormal, and how often

Bars show share of tests flagged abnormal in the selected window.

Regional volume distribution

Where the testing happens

Observed pattern · 01

Liver function testing represents the largest share of GI-related lab volume.

In this illustrative diagnostic-network cohort, LFTs account for 27.8% of GI-relevant orders. Fecal calprotectin shows a higher relative month-on-month increase, but this reflects ordering growth among tested patients, not disease incidence.

Observed pattern · 02

H. pylori stool-antigen positivity varies materially by region.

Among patients who were tested, regional positivity ranges from 56% to 78% in the simulated dataset. These values should be interpreted as denominator-of-tested rates and may be affected by referral, symptom, and access bias.

Observed pattern · 03

GI oncology biomarker testing appears below guideline-eligible targets.

Modelled uptake is 47% for MSI/MMR testing in stage II-III CRC and 58% for HER2 testing in gastric/GEJ cancer. The appropriate interpretation is a potential testing-completeness gap, not a confirmed treatment gap.

LFT abnormality patterns

When liver enzymes are abnormal, what shape do they take?

Distribution of abnormal LFT panels by canonical biochemical pattern.

Viral hepatitis seroprevalence

HBsAg and anti-HCV positivity climbs with age

% of tested patients positive, by age band.

MASLD / NAFLD signal

The steady upward drift of metabolic liver disease

ALT >2x ULN rate, fatty liver index proxies, and GGT elevation are rising annually.

Hepatology · interpretation

Hepatocellular LFT patterns are the largest subgroup in abnormal LFT panels.

In this illustrative cohort, isolated or combined ALT elevation accounts for approximately 58% of abnormal LFT panels. Etiology cannot be inferred from enzymes alone.

Workflow signal

Structured follow-up after incidental ALT elevation may be incomplete.

Approximately one-third of modelled ALT-elevation episodes proceed to fibrosis or viral marker workup. This should be treated as a hypothesis for audit, not a confirmed care-quality measure.

Education signal

Regional variation can inform HCP education planning.

Filtered lab patterns can identify where fibrosis-risk assessment and metabolic comorbidity evaluation may need clearer clinical education.

H. pylori positivity · regional

Regional variation in stool-antigen positivity among tested patients

Rates are calculated only among patients who received testing; they should not be interpreted as population prevalence.

Dyspepsia workup

The de-facto dyspepsia panel in practice

Share of dyspepsia-coded encounters where each test is ordered within 30 days.

Celiac serology · detection trajectory

Testing is up sharply, positivity rate is steady

Volume of tTG-IgA orders versus % positive over five years.

Fecal calprotectin · distribution

The IBS-vs-IBD discriminator in real-world output

Distribution of calprotectin results in all-comer tested population.

Calprotectin x CRP correlation

The two biomarkers track, but not perfectly

Bubble size indicates tested population.

Nutritional deficits

The deficiency layer underneath IBD

Tumor marker activity

Volume x abnormality across GI markers

Order share and abnormality rate across the five GI markers.

CRC CEA testing

CEA testing is rising, but surveillance is rising faster

% of guideline-eligible CRC cases receiving CEA, by indication.

Molecular & biomarker uptake

Observed testing uptake versus guideline-eligible benchmark

Cohort & methodAggregated, de-identified RWD across a pan-India diagnostic network. Tests are routed by GI code and assay mapping.

CaveatsLab-based RWD reflects ordering behaviour, not population prevalence. Read positivity as denominator-of-tested.

Use of this viewDesigned for situational readouts: what is tested, what comes back, and where care gaps live nationally.

PRO / QoL Ready to send IBD · IBS · GERD

Gastro QualLife Questionnaire

Condition-segmented GI quality-of-life survey for patients. It can be distributed to physicians so they can send unique links to their patients, or shared directly with patients as a secure survey link.

Physician-mediated

Send the questionnaire to selected physicians. Each physician receives a workspace to generate initials-only patient links.

Direct patient link

Create a secure shareable link for patient outreach campaigns, reminders, or QR-based field collection.

RWE-ready scoring

Responses feed domain scores for symptom burden, mental wellbeing, functional QoL, financial stress, and treatment experience.

Questionnaire Sections

Consent and survey information

Anonymous research use, estimated 10-12 minutes, voluntary participation.

Patient profile

Age group, gender, diagnosis, condition duration, country, current treatments.

GI symptom burden

6 questions covering frequency, severity, sleep, activities, diet modification, unplanned visits.

Mental wellbeing

7 questions including anxiety, depressive symptoms, stress, frustration, social avoidance, support, doctor discussion.

Functional and social QoL

5 questions on work or study, social plans, relationships, overall QoL, and career impact.

Financial stress

6 questions on care expenses, income impact, delayed care, medication access, financial worry, and provider understanding.

Treatment experience

6 questions on satisfaction, missed doses, understanding, physician communication, treatment changes, and 12-month status.

Distribution Setup

Physician campaign248 verified GI physicians selected

Direct patient URLstudy.gastropulse.in/qol/GQL-2025

Response visibilityDoctors see link status only. Admin sees aggregated analytics.

Protected

Questionnaire Preview

1

How often have your GI symptoms been present in the past 4 weeks?

GI Symptom BurdenScale

NeverRarelySeveral daysMost daysEvery day

2

Over the past 2 weeks, how often have you felt worried, tense, or unsettled?

Mental WellbeingPHQ/GAD proxy

Not at allA few daysAbout half the daysMore than halfNearly every day

3

How much has your GI condition affected your work or study routine in the past month?

Functional QoLScale

No impactSlightModerateConsiderableNot able

4

Have you ever skipped, reduced, or stopped taking prescribed medication because of financial burden?

Financial StressYes/No

YesNo

5

How would you rate how well your current treatment supports control of your GI symptoms?

Treatment ExperienceScale

Very wellWellNeutralNot very wellNot well

Secure patient link GQL-2025 10-12 minutes

GI Patient Quality of Life Survey

This survey asks about GI symptoms, wellbeing, daily activities, financial burden, and treatment experience. Responses are used in aggregated form for research and care-improvement insights.

Survey Landing

Age group

Primary GI diagnosis

Consent

I understand and agree to participate in this survey.

No personally identifiable information is required.

Submission Summary

3

Active Programs

1 enrolling

600

Doctors Targeted

580 verified

314

Doctor Responses

198 KAP complete

203

Patient Links

116 completed

52%

Portfolio Completion

H. pylori dragging

IBS-D KAP Survey 2025

KAPLiveSent 15 Jan

250

Doctors targeted

180

Completed

221

Opened invite

72%

Completion

IBS-D PRO - QoL Assessment

PROLiveLinks from 3 Mar

203

Patient links

116

Patients filled

72

Doctors enabled

58%

Completion

H. pylori Eradication Survey

KAPEnrollingBatch pending

150

Doctors targeted

18

Completed

84

Invites cleared

12%

Completion

Program Name	Type	Condition	Doctors	Responses / Patients	Completion	Status
IBS-D KAP Survey 2025 Created 14 Jan 2025 · Sent 15 Jan	KAP	IBS-D	250	180	72%	Live
IBS-D PRO - QoL Assessment Created 18 Feb 2025 · Links from 3 Mar	PRO	IBS-D	200	116	58%	Live
H. pylori Eradication Survey Created 1 Mar 2025 · First batch pending	KAP	H. pylori	150	18	12%	Enrolling
Constipation Management KAP Created 5 Dec 2024 · Closed benchmark	KAP	Constipation	180	178	99%	Closed

KAP Survey Live IBS-D

IBS-D KAP Survey 2025

To assess gastroenterologist knowledge, attitudes and practices regarding IBS-D diagnosis and management across tier 1, 2 and 3 cities in India.

Created

14 Jan 2025

Sent

15 Jan 2025, 09:00

Closes

30 Jun 2025

Questionnaire

24 questions · 12 min

250

Doctors targeted

248

Invitations sent

221

Opened email

180

Completed responses

Overview

Questionnaire Sent

Doctors & Delivery

Delivery Funnel

Study Setup

Study created

14 Jan 2025 · Demo Account

Questionnaire locked

24 KAP questions · mandatory consent

Doctor list verified

250 uploaded · 248 email IDs verified

Invitations sent

15 Jan 2025, 09:00 · email batch GP-IBS-001

Operational Alerts

Completion is ahead of last KAP benchmark by 9%.

27 verified doctors have not started. Reminder scheduled tomorrow.

Consent capture and anonymisation checks passed.

Completion by City Tier

Doctor Segments

Gastroenterology specialists

180

Internal medicine

45

General physicians

25

Audience uploaded from IBSD_Doctor_Master_Jan2025.xlsx. Two invalid email IDs were excluded before launch.

Doctor	City	Speciality	Invite	Status	Completed
Dr. Rajesh Kumar	Delhi	Gastroenterology	15 Jan, 09:03	Completed	16 Jan, 10:22
Dr. Anita Sharma	Mumbai	Internal Medicine	15 Jan, 09:04	Completed	17 Jan, 14:08
Dr. Suresh Iyer	Bangalore	Gastroenterology	15 Jan, 09:04	Started	-
Dr. Meera Pillai	Chennai	Gastroenterology	15 Jan, 09:05	Not opened	-
Dr. Vikram Patel	Hyderabad	Gastroenterology	Excluded	Invalid email	-

Study Info

2

Form Design

3

Upload Doctors

4

Review & Launch

Form Design

Instrument Library

Custom Builder

Preview

Select validated instruments to include. You can combine multiple.

KAP — Custom GI

Knowledge, Attitude & Practice · 24 Q

IBS-SSS

IBS Symptom Severity Scale · 5 Q

SF-36 v2

Short Form Health Survey · 36 Q

IBS-QoL

Disease-specific Quality of Life · 34 Q

GSRS

GI Symptom Rating Scale · 15 Q

PHQ-9

Patient Health Questionnaire · 9 Q

Bristol Stool Form Scale

Stool classification · 1 Q

Upload custom instrument

Doctor	Hospital	City	Speciality	Email Verified	Studies	Last Response
Dr. Rajesh Kumar DM Gastroenterology	AIIMS Delhi	Delhi	Gastroenterology	Verified	3	Today, 10:22
Dr. Anita Sharma MD Medicine	KEM Hospital	Mumbai	Internal Medicine	Verified	2	Yesterday
Dr. Suresh Iyer DM Gastroenterology	Manipal Hospitals	Bangalore	Gastroenterology	Verified	3	2 days ago
Dr. Meera Pillai MD Gastroenterology	Apollo Hospitals	Chennai	Gastroenterology	Pending	1	—
Dr. Vikram Patel DM Gastroenterology	Fortis Hospitals	Hyderabad	Gastroenterology	Invalid	0	—

203

Links Generated

116

Completed

57%

48

In Progress

39

Not Opened

Reminder due

Link ID	Doctor	Patient Initials	Generated	Link Sent	Status	Completed
PRO-2025-0041	Dr. Rajesh Kumar	A.V.	3 Mar	Sent	Completed	5 Mar, 11:14
PRO-2025-0042	Dr. Rajesh Kumar	S.R.	3 Mar	Sent	In Progress	—
PRO-2025-0043	Dr. Anita Sharma	Not added	4 Mar	Sent	Not Opened	—
PRO-2025-0044	Dr. Suresh Iyer	L.N.	5 Mar	Sent	Completed	6 Mar, 09:32
PRO-2025-0045	Dr. Suresh Iyer	R.K.	5 Mar	Not Sent	Pending	—

Select Study for Analysis

Only the selected study is loaded into the analysis area below. Switching tiles replaces the metrics, intelligence summary, and question-level tiles.

IBS-D KAP Survey 2025

KAPLive

24

Questions

180

Responses

IBS-D PRO - QoL Assessment

PROLive

18

Questions

116

Patients

H. pylori Eradication Survey

KAPEnrolling

18

Questions

18

Responses

Constipation Management KAP

KAPClosed

20

Questions

178

Responses

IBS-D KAP Survey 2025

Showing question-level analysis for this selected study only.

Active filter

4.2 / 5

Average KAP score. Strong knowledge base, but practice consistency varies by city tier.

27%

Do not consistently document baseline stool form and pain severity before treatment.

+14 pts

Tier 1 doctors report higher confidence than Tier 2/3 doctors on differential diagnosis.

Top action

Create a diagnostic checklist and follow-up tracker for lower-volume clinics.

Knowledge vs Practice Gap

Response Quality Signals

Median completion time	11.4 min	Healthy
Low-effort response patterns	3.1%	Low
Open-text richness	64%	Usable
Partial responses	17	Review

No evidence of low-effort response clusters. Most partials drop after the practice section, suggesting survey length is acceptable but final barrier questions may need clearer wording.

Composite Practice Archetypes

Compiled from Q8, Q13, Q16, Q17, Q18. High-confidence doctors do not always run structured follow-up. The best intervention is not more disease education; it is operational tools for documentation and follow-up.

Treatment Choice vs Barrier Cluster

Compiled from Q14, Q15, Q21, Q22. Cost-sensitive physicians select lower-access regimens and request patient handouts more often than digital trackers.

Cohort Heatmap: Where the Gaps Are

Cohort

Knowledge

Confidence

Documentation

Follow-up

Tier 1 GI

86

82

66

61

Tier 2 GI

80

68

58

49

Internal medicine

72

64

44

41

Low-volume clinics

69

52

39

36

Compiled from Q3-Q8 and Q16-Q20. Follow-up structure is the weakest point across cohorts, especially in low-volume clinics.

Intelligence Summary

Knowledge is not the limiting factorRome IV and alarm-feature recognition are reasonably strong. The drop appears when translating knowledge into documentation and monitoring.

Tier drives the operating modelTier 1 doctors show higher confidence and therapy range; Tier 2/3 doctors need lightweight tools that work without specialist support.

Best next actionCreate a one-page diagnostic checklist, baseline severity template, and 2-4 week follow-up reminder workflow.

Patient link experience

Patient opens a unique mobile link and answers one screen at a time

No login. The patient receives a link, sees a consent note, answers the PRO questionnaire, and submits. Try the mobile screen below.

GastroPulseSecure link

IBS-D Quality of Life Assessment

PRO-2025-0042 · No login required

Symptom Severity1 of 5

Thank you. Your response has been submitted.

The study team receives this as an anonymized patient response linked to PRO-2025-0042.

Link received

Patient clicks a unique SMS, WhatsApp, or email link generated by the doctor. There is no patient login step.

Consent first

The opening screen explains confidentiality, estimated time, and that individual answers are not shown back to the doctor.

Question-by-question UI

One question appears per screen with large tap targets, progress indication, and autosave behavior.

Aggregated analytics

Completed responses feed the admin dashboard as question-level tiles, trends, and cohort insights.

Doctor workspace

Doctor sees assigned studies and manages patient links

Doctors do not see patient answers. They can generate patient links, copy/send reminders, and complete any doctor-facing KAP surveys assigned to them.

Assigned Studies

IBS-D PRO - QoL Assessment

72 doctors enabled · patient links open until 30 Jun 2025

H. pylori Eradication Survey

12 questions · pending doctor response

HCP Vignette Survey

NAFLD, GERD, and IBS clinical decision vignettes · 36 questions

IBS-D KAP Survey 2025

Submitted 22 Jan 2025 · response locked

18

Links generated

11

Completed

3

Need reminder

Patient Link Queue

Initials	Status	Action
A.V. PRO-2025-0041	Completed
S.R. PRO-2025-0042	In Progress
Not added PRO-2025-0043	Not Opened

Incoming responses

Submissions become response records and analytics signals

Admins see response arrival, completion quality, and aggregate signals without exposing identifiable patient answers to doctors.

116Completed patient PRO submissions from 203 generated links

92%Responses pass completion quality checks with no missing critical items

31%Report daily activity disruption on 4 or more days per week

Response Stream

AV

PRO-2025-0041 completed

IBS-D QoL Assessment · 7 min 42 sec · all required questions answered

Just now

SR

PRO-2025-0042 saved progress

Question 4 of 5 · symptom severity selected as “Most of the time”

4 min

RK

Doctor KAP response submitted

Dr. Rajesh Kumar · H. pylori Eradication Survey · included one free-text barrier note

18 min

Insight generated

Patients with high urgency scores are 2.1x more likely to report work disruption. Added to Dashboard tile Q3.

Auto

Specialist edition India 25-35 minutes

Gastroenterology HCP Survey

Select an indication card to open the relevant vignette survey. Physicians answer based on real-world practice patterns, treatment preferences, evidence gaps, and decision drivers.

3

Clinical Vignettes

NAFLD · GERD · IBS

36

Decision Questions

12 per vignette

0%

Completion

Answers saved locally

Survey Instructions

Respondent profileGastroenterologist or specialist managing GI/hepatology cases in India.

Response modeSelect the option that best reflects your current practice. Open text boxes capture rationale and unmet needs.

ConfidentialityResponses are shown in aggregate for Medical Affairs, Commercial Strategy, and Academic research purposes.

HCP Survey Submission Summary

Study	Type	Status	Deadline
IBS-D KAP Survey 2025	KAP	Completed	30 Jun 2025
IBS-D PRO — QoL Assessment	PRO	Active	30 Jun 2025
HCP Vignette Survey Vignette NAFLD · Vignette GERD · Vignette IBS	Vignette	In Progress	30 Sep 2025
H. pylori Eradication Survey	KAP	Pending	30 Sep 2025

NAFLD

Selected Vignette

Click a card below to switch

0%

Selected Completion

Answers autosave in this prototype

0/36

Overall Response

All three vignettes assigned

Assigned Vignettes

Doctor Vignette Submission Summary

Each patient receives a unique link. You can optionally record initials for your reference. Patient responses are not visible to you — only aggregated data goes to the study team.

Link ID	Patient Initials	Sent	Status
PRO-2025-0041	A.V.	3 Mar	Completed
PRO-2025-0042	S.R.	3 Mar	In Progress
PRO-2025-0043	Not added	4 Mar	Not Opened
PRO-2025-0044	L.N.	5 Mar	Completed

GastroPulse · IBS-D Quality of Life Assessment

IBS-D Patient Questionnaire

Your unique link: PRO-2025-0042 · Takes about 10 minutes

Section 1 of 3 — Symptom Severity Question 2 of 5

In the last 7 days, how often did your bowel symptoms affect your ability to work or do daily activities?

Not at all

A little of the time

Some of the time

Most of the time

All of the time

Your responses are confidential and will be used only in aggregated form for medical research. Your doctor will not see individual answers.

Study type	KAP Survey
Instrument	KAP - Custom GI
Total questions	24
Mandatory questions	22
Estimated time	12 minutes
Languages	English
Sent via	Email invitation with unique doctor link

What gastroenterology orders look like, in volume

Demand has been climbing, with calprotectin and molecular fastest

What is coming back abnormal, and how often

Where the testing happens

Liver function testing represents the largest share of GI-related lab volume.

H. pylori stool-antigen positivity varies materially by region.

GI oncology biomarker testing appears below guideline-eligible targets.

When liver enzymes are abnormal, what shape do they take?

HBsAg and anti-HCV positivity climbs with age

The steady upward drift of metabolic liver disease

Hepatocellular LFT patterns are the largest subgroup in abnormal LFT panels.

Structured follow-up after incidental ALT elevation may be incomplete.

Regional variation can inform HCP education planning.

Regional variation in stool-antigen positivity among tested patients

The de-facto dyspepsia panel in practice

Testing is up sharply, positivity rate is steady

The IBS-vs-IBD discriminator in real-world output

The two biomarkers track, but not perfectly

The deficiency layer underneath IBD

Volume x abnormality across GI markers

CEA testing is rising, but surveillance is rising faster

Observed testing uptake versus guideline-eligible benchmark

Gastro QualLife Questionnaire

GI Patient Quality of Life Survey

IBS-D KAP Survey 2025

IBS-D Knowledge, Attitudes & Practices Survey

Gastroenterology HCP Survey

IBS-D Patient Questionnaire